Tuesday, June 19, 2018 6:19:48 AM
SEC. 504. The Biomedical Advanced Research and Development Authority and the BioShield Special Reserve Fund.
(a) Bioshield special reserve fund.—Section 319F–2(g)(1) (42 U.S.C. 247d–6b(g)(1)) is amended—
(1) by striking “$2,800,000,000 for the period of fiscal years 2014 through 2018” and inserting “$3,500,000,000 for the period of fiscal years 2019 through 2023, to remain available until expended”; and
(2) by striking the second sentence.
(b) The Biomedical Advanced Research and Development Authority.—Section 319L(d)(2) (42 U.S.C. 247d–7e(d)(2)) is amended by striking “$415,000,000 for each of fiscal years 2014 through 2018” and inserting “$611,700,000 for each of fiscal years 2019 through 2023”.
https://www.congress.gov/bill/115th-congress/senate-bill/2852/text#toc-id34BAC41C46EF4F6587D36B5BDA32E3DC
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM